Pharmaceutical - Cardio-vascular, Respiratory and Pulmonary

Filter

Popular Filters

New Zealand's PHARMAC funds four new medicines as part of major agreement with Novartis

New Zealand's PHARMAC funds four new medicines as part of major agreement with Novartis

20-10-2014

New Zealand's Pharmaceutical Managment Agency PHARMAC has agreed to fund four new medicines for which…

Antibiotics and Infectious diseasesCardio-vascularglycopyrroniumindacaterolNew ZealandNovartisOmalizumabPharmaceuticalRegulationRespiratory and PulmonaryTobramycin

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline

15-05-2014

Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

Pharmacovigilance Risk Assessment Committee April meeting highlights

Pharmacovigilance Risk Assessment Committee April meeting highlights

11-04-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) gave a recommendation…

Cardio-vascularEuropeMen's HealthNeurologicalPharmaceuticalRegulationRespiratory and Pulmonary

MedImmune joins research collaboration with the University of California

MedImmune joins research collaboration with the University of California

17-02-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

Antibiotics and Infectious diseasesCardio-vascularInflammatory diseasesMedImmuneMetabolicsNeurologicalOncologyPharmaceuticalResearchRespiratory and PulmonaryUSA

Return to growth: AstraZeneca’s CEO Pascal Soriot says 2013 was year of “momentum” for the company

Return to growth: AstraZeneca’s CEO Pascal Soriot says 2013 was year of “momentum” for the company

06-02-2014

‘Momentum’ is the word which best describes 2013, according to AstraZeneca’s chief executive Pascal…

AstraZenecaBrilintaCardio-vascularCrestorDiabetesExenatide InjectionFinancialInterviewsNexiumOncologyPharmaceuticalRespiratory and PulmonarySymbicortUK

EMA/CHMP gives Novartis positive opinion for Xolair; negative opinion on RLX030 to be appealed

EMA/CHMP gives Novartis positive opinion for Xolair; negative opinion on RLX030 to be appealed

24-01-2014

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has given…

Cardio-vascularEuropeNovartisPharmaceuticalRegulationRespiratory and PulmonaryXolair

Forest Laboratories announces new appointments to its executive team

16-12-2013

New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments…

Anti-viralsBoardroomCardio-vascularCNS DiseasesForest LaboratoriesGastro-intestinalsPharmaceuticalRespiratory and PulmonaryUSA

FDA approves Bayer’s Adempas; firm accelerates drug candidates

FDA approves Bayer’s Adempas; firm accelerates drug candidates

09-10-2013

The US Food and Drug Administration late yesterday approved Adempas (riociguat), developed by German…

AdempasBayerCardio-vascularcopanlisibfinerenoneNorth AmericaOncologyPharmaceuticalRegulationResearchRespiratory and PulmonaryWomen's Health

Further highlights from European Society of Cardiology meeting

03-09-2013

The ongoing European Society of Cardiology meeting in Amsterdam, Netherlands, continues to produce both…

ActelionalogliptinAmgenBiotechnologyCardio-vascularCytokineticsDiabetesomecamtiv mecarbilOpsumitPharmaceuticalResearchRespiratory and PulmonaryTakeda Pharmaceuticals

Akrikhin expands deal with Merck & Co

08-08-2013

Leading Russian drugmaker Akrikhin says it has expanded its partnership with US pharma giant Merck &…

Akrikhin PharmaceuticalsCardio-vascularDiabetesEuropeEzetrolJanumetJanuviaMarkets & MarketingMerck & CoNoxafilPharmaceuticalProductionRespiratory and PulmonarySingulair

Merck & Co opens new $120 million manufacturing plant in China

19-04-2013

US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Japanese approvals for Eylea, Tresiba, Seebri and Aimix

01-10-2012

There was a flurry of announcements from Japan's Ministry of Health, Labor and Welfare (MHLW) on Friday,…

AimixAsia-PacificBayerCardio-vascularDainippon Sumitomo PharmaDiabetesEyleaNovartisNovo NordiskOphthalmicsPharmaceuticalRegeneronRegulationRespiratory and PulmonarySeebri BreezhalerShionogiTresibaVectura

Unigene and Tarix report highly increased oral bioavailability of "Peptelligence-engineered" TXA127

20-09-2012

USA-based Unigene Laboratories Laboratories (OTCBB: UGNE) and Tarix Pharmaceuticals yesterday announced…

Cardio-vascularLicensingPharmaceuticalResearchRespiratory and PulmonaryTarix PharmaceuticalsTXA127Unigene Labs

NICE now backs Xarelto to treat blood clots; negative on Bronchitol for CF

01-06-2012

In final draft guidance published today (1 June 1), UK drugs watchdog the National Institute for Health…

BayerBronchitolCardio-vascularEuropePharmaceuticalPharmaxisPricingRare diseasesRegulationRespiratory and PulmonaryXarelto

Strong results for Bayer's Xarelto in treating pulmonary blood clots

27-03-2012

German drugs and crops sciences group Bayer (BAY: DE), and partner Janssen, part of US health care major…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalRegulationResearchRespiratory and PulmonaryXarelto

B-MS ties knot with Duke University on R&D

29-02-2012

Bristol-Myers Squibb has forged a partnership with Duke University in the USA that will see the academic…

Bristol-Myers SquibbCardio-vascularGeneralHomeLysophosphatidic acid 1 (LPA1)MetabolicsOncologyPfizerPharmaceuticalRespiratory and PulmonarySanofi

NICE publishes final technology appraisal guidance for four conditions

24-01-2012

The UK’s drugs watch dog the National Institute for Health and Clinical Excellence (NICE) has today…

AvastinCardio-vascularDaxasEliquisErbituxEuropeOncologyPharmaceuticalPricingRegulationRespiratory and PulmonaryRituxanVectibix

Back to top